Core Viewpoint - Company plans to invest up to RMB 60 million to establish a venture capital partnership named Shanghai Delian Bojian Venture Capital Partnership (Limited Partnership), holding a 20% stake in the fund [1][2][3] Investment Overview - The investment aims to enhance industrial innovation and incubation, expanding the "base + fund" and "investment + incubation" investment system, particularly in the brain science industry cluster [2][16] - The total fund size is RMB 300 million, with the first phase being an expansion period after one year [3][4] Fund Structure - The fund's contributors include Shanghai Future Qidian Private Investment Fund Partnership (40%), Sanbo Brain Hospital Management Group (29%), Company (20%), and others [4][12] - The fund will primarily invest in early-stage and growth-stage companies in the brain science sector, focusing on tools, neuroscience, and mental system diseases [11][14] Management and Operations - The fund's general partner is Shanghai Huchuang Bolian Management Consulting Partnership (Limited Partnership), and the fund manager is Dazi Delian Investment Management Co., Ltd. [6][9] - The fund will have an investment period of 4 years and an exit period of 4 years, with a possible extension of 1+1 year [11][14] Financial Implications - The company will bear investment risks up to the amount of RMB 60 million, which will not adversely affect its normal operations or cash flow [15][16] - The investment is expected to optimize the company's investment structure and accelerate the establishment of the brain science industry cluster in the North High-tech Park [16]

Group 1 - The company plans to invest up to RMB 60 million to establish Shanghai Delian Bojian Venture Capital Partnership (Limited Partnership), holding a 20% stake in the partnership [1] - The total fund size is RMB 300 million, focusing on investment in the brain science industry, including tool-level enterprises, neuroscience, mental system diseases, and cutting-edge brain science in the future health sector [1] - This investment will not affect the company's normal production and operation activities, nor will it have a significant adverse impact on the company's cash flow and operating performance, aligning with the interests of the company and all shareholders [1]